Cipro Hc Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber, few things are more frustrating than writing a prescription only to have your patient call back saying the pharmacy can't fill it. Cipro Hc (Ciprofloxacin HCl 0.2%/Hydrocortisone 1% otic suspension) has been a source of that frustration for many providers over the past several years.

This briefing covers the current state of Cipro Hc availability, the landmark generic approval, prescribing considerations, cost implications for patients, and clinical tools to help your practice manage ear infection treatment in 2026.

Timeline: How We Got Here

Cipro Hc was originally approved by the FDA and marketed by Novartis as a brand-name product. For decades, it remained a single-source medication — no generic alternatives existed for this specific formulation of Ciprofloxacin with Hydrocortisone in an otic suspension.

Key milestones:

• Original approval: Cipro Hc Otic was approved by the FDA for the treatment of acute otitis externa
• Years of single-source supply: As the only manufacturer, Novartis controlled the entire supply chain. Any production issues resulted in pharmacy-level stockouts across the country.
• December 16, 2025: The FDA approved Cosette Pharmaceuticals' ANDA for the first generic version of Cipro Hc, granting 180 days of Competitive Generic Therapy (CGT) exclusivity.
• Early 2026: The Cosette generic is in active distribution, with availability expanding to pharmacies and wholesalers nationwide.

Prescribing Implications

Generic Substitution

With the Cosette generic now available, pharmacists in most states can automatically substitute the generic for brand-name Cipro Hc unless you specify "Dispense As Written" (DAW) or "brand name medically necessary." For the vast majority of patients, the generic is appropriate and will significantly reduce out-of-pocket costs.

Recommendation: Unless there's a specific clinical reason to require the brand, allow generic substitution. This improves fill rates and reduces patient financial burden.

Prescribing by Generic Name

Consider writing prescriptions as "Ciprofloxacin HCl 0.2%/Hydrocortisone 1% otic suspension" rather than the brand name. This gives pharmacists maximum flexibility to dispense whichever manufacturer's product they have in stock.

When to Prescribe Cipro Hc vs. Alternatives

Cipro Hc remains a strong first-line option for uncomplicated acute otitis externa. However, consider these clinical scenarios:

• Intact tympanic membrane + otitis externa: Cipro Hc is appropriate
• Perforated tympanic membrane: Cipro Hc is contraindicated (nonsterile formulation). Consider Ofloxacin otic or Ciprodex instead.
• Otitis media with tympanostomy tubes: Cipro Hc is not FDA-approved for this indication. Ciprodex or Ofloxacin are preferred.
• Significant inflammation/granulation tissue: Ciprodex (with the more potent Dexamethasone) may provide superior anti-inflammatory effect.
• Cost-sensitive patients: Ofloxacin otic ($15–$30) or generic Cortisporin Otic ($15–$30) offer substantial savings over Cipro Hc.

For a detailed comparison of alternatives, see our clinical guide on alternatives to Cipro Hc.

Current Availability Picture

As of early 2026:

• No active FDA shortage for Cipro Hc
• Cosette generic is in active distribution with expanding pharmacy coverage
• Brand Cipro Hc remains available through Novartis
• Pharmacy-level stockouts persist at some locations, particularly large chains that use automated inventory systems and don't routinely stock specialty otic preparations

Pharmacies near ENT practices and pediatric clinics are more likely to carry Cipro Hc consistently. Independent pharmacies also tend to have more flexible ordering capabilities.

Cost and Access Considerations

Cost remains a significant barrier for many patients:

• Brand retail price: $344–$364 per 10 mL bottle
• With coupon (GoodRx): As low as $69
• Generic (Cosette): Expected to be 40–50% below brand retail, with further discounts available through coupon cards
• Ofloxacin otic (generic): $15–$30 — the most affordable fluoroquinolone otic option
• Patient assistance: Novartis Patient Assistance Foundation (1-800-277-2254) provides the medication at no cost for qualifying uninsured/underinsured patients

Many insurance plans cover Cipro Hc on Tier 2 or Tier 3, though some require prior authorization or prefer step therapy with Ofloxacin first. The generic approval should improve formulary positioning over time.

For specific savings strategies to share with patients, see our article on saving money on Cipro Hc.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-focused tool that helps you and your staff check real-time pharmacy availability for Cipro Hc and other medications. Instead of having patients call multiple pharmacies, you can direct them to a pharmacy that has it in stock — or send the prescription there directly.

This is particularly useful for:

• Same-day treatment of acute otitis externa
• Patients who've already been turned away by one pharmacy
• Practices in areas with limited pharmacy options

Patient Education Resources

Consider directing patients to these resources:

• What is Cipro Hc? — comprehensive patient-friendly overview
• Cipro Hc side effects — what patients should watch for
• Cipro Hc drug interactions — safety information
• How to find Cipro Hc in stock — practical tips for patients

Looking Ahead

The Cipro Hc market is evolving in patients' favor. With the Cosette generic now available and CGT exclusivity expiring in mid-2026, additional generic manufacturers may enter the market, further improving supply and driving down prices.

Providers should anticipate:

• Improved pharmacy stocking as the generic gains traction
• Potential for additional generic approvals in late 2026 or 2027
• Better insurance formulary positioning for the generic
• Continued summer demand spikes — plan accordingly for seasonal prescribing patterns

Final Thoughts

Cipro Hc remains a valuable tool in your otic infection armamentarium. The December 2025 generic approval is the most significant development for this medication in years, addressing both the supply and cost barriers that have plagued patients and providers alike.

Leverage tools like Medfinder for Providers to streamline the prescription-to-fill process, and consider prescribing by generic name to maximize your patients' chances of a successful pharmacy fill. For a detailed provider guide on helping patients locate this medication, see our article on how to help your patients find Cipro Hc in stock.